Same Indication

Nivolumab vs Sitagliptin

Nivolumab vs Sitagliptin: Overview

This comparison examines the pharmacological differences between Nivolumab and Sitagliptin.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Sitagliptin: DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days; Sitagliptin β€” 12.4 hours.

Chemical Properties

Molecular Formula: Sitagliptin β€” C16H15F6N5O.

Molecular Weight: Sitagliptin β€” 407.3140 g/mol.

Type: Nivolumab β€” Antibody; Sitagliptin β€” Small molecule.